The purpose of this research study is to compare two different combinations of anesthetic medications to see which works the best in providing the longest lasting pain relief for total knee arthroplasty surgery. The drugs being used are liposomal bupivacaine compared to a combination of bupivacaine, clonidine, epinephrine, buprenorphine, and dexamethasone. Pain scores will be collected at different intervals during study participation.

Start Date01 Apr 2026

Sponsor / Collaborator

Wake Forest School of Medicine

NCT07432711

/ Not yet recruitingNot ApplicableIIT

The Efficacy and Safety of Liposomal Bupivacaine Plus Bupivacaine Local Incisional Infiltration for Postoperative Pain in Patients Undergoing Video-assisted Thoracoscopic Surgery:A Multi-Center Randomized Controlled Trial

Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy. It is reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process.If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Local infiltration anesthesia at the incision site is one of the simplest, safest, and most effective methods for preventing postoperative incision pain. Liposomal bupivacaine(LB) is a novel, long-acting, sustained-release amide-type local anesthetic, providing localized analgesic effects for up to 72 hours. Some researchers have reported the analgesic effects of LB VS traditional local anesthetics infiltration, but the current research results are highly heterogeneous. More prospective studies are needed to evaluate whether LB infiltration is superior to the traditional local anesthetics for the management of postoperative pain. The investigators designed this study to compare the analgesic effect of using LB plus bupivacaine for local infiltration with bupivacaine along for patients after VATS.

Start Date15 Feb 2026

Sponsor / Collaborator

Beijing Tiantan Hospital

ChiCTR2600118207

/ Not yet recruitingNot ApplicableIIT

Effects of bupivacaine liposome used for quadratus lumborum muscle block on the quality of recovery and gastrointestinal barrier function in elderly patients undergoing colorectal cancer surgery

Start Date05 Feb 2026

Sponsor / Collaborator

The First People's Hospital of Changzhou

100 Clinical Results associated with Bupivacaine liposome

100 Translational Medicine associated with Bupivacaine liposome

100 Patents (Medical) associated with Bupivacaine liposome

945

Literatures (Medical) associated with Bupivacaine liposome

31 Dec 2026·ANNALS OF MEDICINE

Comparison of liposomal bupivacaine and bupivacaine hydrochloride intercostal nerve blocks for postoperative analgesia after thoracic surgery: a multicenter, randomized, three arms trial protocol

Article

Author: Wang, Lihua ; Huang, Junyi ; Lv, Xin ; Yang, Yiming ; Liu, Hang ; Xin, Yuxuan ; Wei, Shiyou ; Chang, Rui ; Song, Jiong

INTRODUCTION:

Whether intercostal nerve block can fully realize the prolonged analgesic potential of liposomal bupivacaine remains uncertain. This study aims to evaluate whether liposomal bupivacaine administered via intercostal nerve block confers a long-acting analgesic advantage over bupivacaine hydrochloride and no block within the postoperative 25-72 h window.

PATIENTS AND METHODS:

This is a multicenter, randomized, parallel, three-arm controlled trial planning to enroll 210 patients undergoing elective unilateral video-assisted thoracoscopic surgery. Using center-stratified block randomization (1:1:1), patients will be allocated at the end of surgery to receive an intercostal nerve block with liposomal bupivacaine, bupivacaine hydrochloride, or no block. All patients will follow a standardized general anesthesia and multimodal analgesia protocol. The primary outcome is the area under the curve for pain scores during the postoperative 25-72 h. Other outcomes include pain verbal response scale at predefined time points, cumulative postoperative morphine milligram equivalent consumption, sensory block recovery time, 15-item quality of recovery scale, postoperative nausea and vomiting, postoperative pulmonary complications, length of hospital stay.

DISCUSSION:

This study prospectively evaluates the central question of whether liposomal bupivacaine confers a clinically meaningful long-acting analgesic advantage when used in the context of nerve block. By focusing on the area under the curve of pain scores and incorporating patient-centered outcomes such as opioid consumption and quality of recovery, the study aims to generate high-quality, translatable evidence to define the role of liposomal bupivacaine in thoracic surgery.

CLINICAL TRIAL REGISTRATION:

Clinicaltrials.org, NCT07134660.

01 Jun 2026·KNEE

Liposomal bupivacaine reduced postoperative analgesia in patients undergoing knee arthroplasty

Review

Author: Daniels, Alan H ; Sebaaly, Amer ; Nakouzi, Matthew ; El-Othmani, Mouhanad M ; Daher, Mohammad ; Mansour, Jad ; Liu, Jonathan ; Estephan, Michel

BACKGROUND:

Liposomal bupivacaine (LB), a sustained-release formulation, is designed to prolong regional analgesia, and has been investigated as a solution for perioperative pain management. This meta-analysis of randomized controlled trials (RCTs) assessed the benefits of LB in patients undergoing knee arthroplasty.

METHODS:

Following the PRISMA guidelines, PubMed, Cochrane, and Google Scholar were accessed and explored until November 2025. The extracted data consisted of the risk of nausea/vomiting (N/V), length of stay (LOS), and postoperative pain and opioid consumption at 1, 2, and 3 days postoperatively.

RESULTS:

Six RCTs were included, consisting of 311 in the LB group and 318 in the control group. There was no difference between the two groups in N/V or LOS. However, patients receiving LB had less pain compared with patients receiving ropivacaine at 1 day postoperatively (standardized mean difference = -0.69, P = 0.03), and less pain compared with the control groups as a whole 2 days postoperatively (standardized mean difference = -0.44, P < 0.001). Opioid consumption was lower in the LB group compared with the group receiving standard bupivacaine at 1, 2, and 3 days postoperatively (mean difference = -11.52 morphine milligram equivalents (MME), mean difference = -9.02 MME, mean difference = -4.58 MME, P < 0.001 respectively). Similarly, Opioid consumption was lower in the LB group compared with the control group as a whole at 2 and 3 days postoperatively (mean difference = -7.01 MME, P = 0.02; mean difference = -4.59 MME, P < 0.001, respectively).

CONCLUSION:

LB reduces postoperative pain and opioid consumption after knee arthroplasty with no increased risk of N/V.

01 Apr 2026·SURGERY

Local infiltration of liposomal bupivacaine is associated with reduced postoperative admission in anterior abdominal hernia repair

Article

Author: Wolansky, Rachel L ; Kendall, Melissa A ; Sujka, Joseph ; Zander, Tyler ; Grimsley, Emily A ; Torikashvili, Johnathan V ; Kuo, Paul C

News (Medical) associated with Bupivacaine liposome

12 Feb 2026

·www.globenewswire.com

Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction (“NOPAIN”) Act. Made up of more than 250 organizations dedicated to preventing opioid addiction before it starts, Voices is the nation’s leading nonpartisan coalition dedicated to ensuring patient access to non-addictive pain management approaches Data were gathered from a national awareness, trial, and usage (ATU) survey of nearly 750 hospitals, health systems, and ambulatory surgery center (ASC) directors of pharmacy, medical directors, surgeons, and anesthesiologists. Results illustrate the early impacts of the NOPAIN Act, which went into effect on January 1, 2025, with key highlights including: Eighty-five percent of facility representatives surveyed were aware of the legislation, and more than half (52 percent) of facilities surveyed had taken steps to increase utilization of qualifying non-opioid options.More than 80 percent of those surveyed reported that the legislation has decreased opioid prescribing immediately after surgery (83 percent) and at discharge (88 percent); andThe majority of respondents report changing perioperative and postoperative pain management protocols (52 and 51 percent, respectively) to increase the use of non-opioids and decrease the use of opioids. “The NOPAIN Act is a pivotal step forward for patients and for Pacira’s mission,” said Frank D. Lee, Chief Executive Officer at Pacira. “We are already seeing clear evidence that this policy is providing an important catalyst for expanding access to safe, effective non-opioid pain management options for Medicare patients, with commercial payers increasingly recognizing the value and following suit.” “We are very encouraged to see the NOPAIN Act delivering on its core promise of reducing our reliance on opioids in the postsurgical setting,” said Chris Fox, Executive Director of Voices for Non-Opioid Choices. “By reducing our overreliance on prescription opioids, we can prevent opioid addiction and save lives. We remain committed to working alongside providers, patients, and facilities to advance access to non-opioid options, and look forward to consistently tracking the growing impact of this important reimbursement policy.” Signed into law as part of the Consolidated Appropriations Act of 2023, the NOPAIN Act sought to prevent opioid addiction by increasing access to qualifying non-opioid pain management options for Medicare beneficiaries undergoing surgery in ASC and hospital outpatient department settings. For more information on the ATU, including the complete results, click here. About PaciraPacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com. About Voices for Non-Opioid ChoicesVoices for Non-Opioid Choices is a nonpartisan coalition dedicated to preventing opioid addiction before it starts by increasing patient and provider access to non-opioid therapies and approaches to manage acute pain. For more information, visit www.nonopioidchoices.org. Forward-Looking StatementsAny statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the contributions of new directors; '5x30', our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including PCRX-201; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company and the anticipated funding or benefits of our share repurchase program. and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the SEC. Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com

Phase 2

28 Jan 2026

·www.globenewswire.com

Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company’s Board of Directors to 10 members. “Samit is an accomplished and widely respected leader in the biopharmaceutical industry, and we are pleased to welcome him to our Board of Directors,” said Laura Brege, independent board chair of Pacira. “We believe his deep clinical development expertise and longstanding commitment to advancing innovative, patient‑centric therapies will make him an invaluable addition to our organization. We look forward to drawing on his insight and leadership as we accelerate the growth of our robust portfolio and pipeline of non‑opioid pain solutions and continue to elevate the standard of care for patients.” “I’m excited to be joining Pacira’s Board during this pivotal time in the Company’s evolution,” said Dr. Hirawat. “Pacira stands at the forefront of non‑opioid pain management, driven by an industry‑leading commercial portfolio and an exceptionally promising pipeline of innovative pain solutions, including next‑generation gene therapies. I look forward to collaborating with this talented leadership team and contributing my experience to help advance Pacira’s mission to fundamentally transform how pain is treated for patients around the world.” Most recently, Dr. Hirawat served as Chief Medical Officer, Executive Vice President, and Head of Global Drug Development at Bristol Myers Squibb, where he oversaw the worldwide clinical development portfolio and advanced multiple transformative therapies across therapeutic areas. Prior to that, he spent more than a decade at Novartis Pharmaceuticals in roles of increasing strategic and operational responsibility, culminating in his position as Executive Vice President and Head of Oncology Development. Dr. Hirawat earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Sawai Man Singh Medical College, where he also trained as a Resident in General Surgery. He conducted his Internal Medicine residency and Medical Oncology fellowship at North Shore University Hospital. Dr. Hirawat has published more than 150 peer-reviewed manuscripts and abstracts across therapeutic areas. About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com. Forward-Looking Statements Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the contributions of new directors; '5x30', our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (“NOPAIN”) Act and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH; risks associated with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera° and any of our other product candidates, including PCRX-201; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company and the anticipated funding or benefits of our share repurchase program. and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the SEC. Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Sara Marino, (973) 370-5430 sara.marino@pacira.com

Executive ChangePhase 2

13 Jan 2026

·www.biospace.com

Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL ® (bupivacaine liposome injectable suspension), Pacira’s long-acting, local analgesic for postsurgical pain management in the region. “We are excited to launch this key regional partnership that significantly expands patient access to opioid-sparing pain management and advances our 5x30 strategy. LG Chem is an established leader in pain management with a proven track record of delivering orthopedic pain solutions to patients across Asia,” said Frank D. Lee, chief executive officer of Pacira BioSciences. “By leveraging LG Chem’s decades of experience in the orthopedic and surgical markets, we will greatly broaden the availability of EXPAREL in a part of the world where there is a significant unmet need for long-acting postsurgical pain control and enhanced recovery.” “Current analgesics are constrained by short duration and limited efficacy, underscoring the market’s need for better postsurgical pain control,” said Inchul Hwang, Vice President and Head of Primary Care Business Unit of LG Chem Life Sciences. “We are delighted to join forces with Pacira and believe we are ideally suited to leverage our leadership in pain management to greatly expand patient access to EXPAREL. This partnership directly aligns with our commitment to advancing patient care through innovative product offerings.” Under the terms of the agreement, Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future commercial sales by LG Chem in licensed territories. Pacira will manufacture EXPAREL. LG Chem will be responsible for securing regulatory approvals in the licensed territories and plans to marketing authorizations in South Korea and Thailand within the next six months. About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL ® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera ® º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit . Forward-Looking Statements Any statements in this press release about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the settlement described herein, ‘5x30’, our growth and business strategy; our future outlook, our intellectual property and patent terms, our growth and future operating results and trends, our strategy, plans, objectives, expectations (financial or otherwise) and intentions, future financial results and growth potential, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio, development programs, development of products, strategic alliances and other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: the failure to realize the anticipated benefits and synergies from the acquisition of GQ Bio Therapeutics GmbH; risks associated with acquisitions, such as the risk that the acquired businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and U.S. economic conditions (including inflation and rising interest rates), and our business, including our revenues, financial condition, cash flow and results of operations; the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U.S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of our products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the Securities and Exchange Commission (the “SEC”). In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the “Risk Factors” of our most recent Annual Report on Form 10-K and in other filings that we periodically make with the SEC. CONTACT: Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com Media Contact: Kim Hamilton, (908) 721-7067 kim.hamilton@pacira.com

License out/inDrug ApprovalPhase 2

100 Deals associated with Bupivacaine liposome

External Link

KEGG	Wiki	ATC	Drug Bank
D07552	Bupivacaine liposome	N01BB01	DB00297

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	United States	Pacira Biosciences, Inc.	28 Oct 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Back Pain	Phase 3	United States	Pacira Biosciences, Inc.	30 Apr 2024
Pain	Phase 3	United States	Pacira Biosciences, Inc.	22 Oct 2021
Analgesia	Phase 3	United States	Pacira Biosciences, Inc.	14 Apr 2021
Leg Injuries	Phase 3	United States	Pacira Biosciences, Inc.	20 Oct 2020
Female Genital Neoplasms	Phase 3	United States	Pacira Biosciences, Inc.	31 Aug 2016
Brachial Plexus Neuritis	Phase 3	Belgium	Pacira Biosciences, Inc.	27 Apr 2016
Toothache	Phase 3	United States	Pacira Biosciences, Inc.	01 Aug 2015
Bunion	Phase 3	United States	Pacira Biosciences, Inc.	01 Apr 2009
Hallux Valgus	Phase 3	United States	Pacira Biosciences, Inc.	01 Apr 2009
Dupuytren Contracture	Phase 2	Belgium	Pacira Biosciences, Inc.	02 Jan 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05140499 (CTgov)	Phase 4	Pain, Postoperative	11	Liposomal bupivacaine (Single Shot Perineural Popliteal Nerve Block)	kgvqlzftok(spqotfeyzg) = vwcmelhrro kolbojdsci (cgbkofwcyo, 3.07) View more	-	27 Jan 2026
				Bupivacaine Hydrochloride (Continuous Perineural Popliteal Nerve Block Catheter)	kgvqlzftok(spqotfeyzg) = uwhcnrtaxd kolbojdsci (cgbkofwcyo, 3.32) View more
NCT03599635 (CTgov)	Phase 4	Acute Pain	112	saline+epinephrine+Fentanyl+Midazolam+bupivacaine (EVEN Number = PEC Block)	fvvwnpyodr(bwoerdaoyy) = nkpueltkai wnmsejxqop (vnlhcqrfzk, dbrhapxyon - lijhoogkwv) View more	-	11 Dec 2025
				liposomal bupivacaine+epinephrine+bupivacaine (ODD Number = Surgeon Infiltration)	fvvwnpyodr(bwoerdaoyy) = pgoqfvtjkc wnmsejxqop (vnlhcqrfzk, cmeahuothg - nyofueoxzp) View more
NCT04333095 (CTgov)	Phase 4	Cardiovascular Diseases \| occlusions \| Pain, Postoperative	70	Liposomal bupivacaine (Liposomal Bupivacaine Block)	llhjinpylp(vifteueuyl) = bsjsiprogj kajpsoftkn (uszchtmgbb, 16.3) View more	-	22 Oct 2025
				Normal Saline Flush, 0.9% Injectable Solution_#1 (Saline Block)	llhjinpylp(vifteueuyl) = cspakhwrwu kajpsoftkn (uszchtmgbb, 10.4) View more
NCT03827291 (CTgov)	Phase 4	Analgesia	35	Exparel (Quadratus Lumborum Block)	gbxwlmuigx(lgdoodxroz) = fwblzcjfgs smncdpqwdf (vkrmsqmqrx, swttbmwams - scrercrcwy) View more	-	16 Oct 2025
				Thoracic epidural analgesia (Thoracic Epidural Analgesia)	gbxwlmuigx(lgdoodxroz) = kkufqtvami smncdpqwdf (vkrmsqmqrx, jccjrnxggt - nwncckopgg) View more
NCT02128646 (CTgov)	Phase 4	Hernia, Ventral \| Pain, Postoperative	19	Exparel (Laparoscopic Control Arm)	finafalzfv(cbrphvcdcv) = ydeyrjonzd yzqrozoozv (enboomsqlu, yowrbhmrrx - xdnxrvuroh) View more	-	10 Sep 2025
				Fentanyl+Exparel+Ketorolac (Laparoscopic Treatment Arm)	finafalzfv(cbrphvcdcv) = ggnrzekkew yzqrozoozv (enboomsqlu, rsyaecurox - fgidujneul) View more
NCT05157841 (CTgov)	Phase 3	Hallux Valgus \| Pain, Postoperative	185	Bupivacaine liposome injectable suspension 266 mg	fbbftyeniy(xnzsqmjyws) = rdotvtradz dehysbspap (uyiellukfj, 265.35) View more	-	26 Jun 2025
NCT04559347 (CTgov)	Phase 2	Thoracic Diseases	45	Liposomal Bupivacaine (EXPAREL®)/Bupivacaine (Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine)	glmkngtvtc(gnfiuxdzqr) = frczfaxiyv zmgiakwexb (wdasavbpgy, 2.531) View more	-	12 Jun 2025
				Ropivacaine (Continuous Catheter Infusion Ropivacaine)	glmkngtvtc(gnfiuxdzqr) = rytczhupud zmgiakwexb (wdasavbpgy, 2.744) View more
NCT05537883 (TAP, CTgov)	Phase 1	Obesity, Morbid	72	Bupivacaine Injection (Bupivacaine Only)	nygcnoybqg(tbpdzrxmyb) = bodbrjehva uofpgowrcj (atmkkngksn, cqhdtfsdjf - jwrbpptgog) View more	-	11 Jun 2025
				Liposomal bupivacaine (Liposomal Bupivacaine)	nygcnoybqg(tbpdzrxmyb) = tpwddpnqmp uofpgowrcj (atmkkngksn, sfejyaaezs - stgluecujx) View more
NCT04685876 (CLEVELAND, CTgov)	Phase 3	-	285	Liposomal bupivacaine (Liposomal Bupivacaine)	vcgqdnkehc(brwkguolhp) = uerecgxniy auifhnjpwt (ughjaqmjxr, wpxpphpnei - xzlssrzxyq) View more	-	07 May 2025
				Plain bupivacaine (Plain Bupivacaine)	vcgqdnkehc(brwkguolhp) = mowmqhseaf auifhnjpwt (ughjaqmjxr, unvojsbwpr - owdbbeocyh) View more
NCT03290196 (CTgov)	Phase 4	Rotator Cuff Tear Arthropathy \| Pain, Postoperative	13	EXPAREL	djhoggzzjz(yvkfuduwyc) = dtwvxnqudv upyzliabhc (baifahhixg, 3.0) View more	-	30 Mar 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis